Nucleic Acid Therapeutics CDMO Market | Size, Share and Scope Analysis to 2031

"Global Nucleic Acid Therapeutics CDMO Market By Technology (Column-Based Method and Microarray-Based Method), Products (Standard Nucleic Acid, Micro-Scale Nucleic Acid, Large-Scale Nucleic Acid, Custom Nucleic Acid, Modified Nucleic Acid, Primers, Probes, Other Nucleic Acid, and Other Services), End-users (Pharmaceutical Companies, Academic Research Institute, Diagnostic Laboratories) Chemical Synthesis (Solid-Phase Oligonucleotide Synthesis, Liquid-Phase Oligonucleotide Synthesis) - By Trends, Industry Competition Analysis, Revenue and Forecast Till 2031"

According to the latest research by InsightAce Analytic, the global nucleic acid therapeutics CDMO market size valued at US$ 1.93 billion in 2021 and it is expected to reach US$ 4.69 billion in 2030, recording a promising CAGR of 10.7% during the period of 2023-2031.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1348

Numerous genetic disorders are typically treated with nucleic acid therapeutics. The high prevalence of chronic and genetic diseases increases the demand for nucleic acid therapeutic applications. Nucleic acid therapeutics are derived from deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or other chemical compounds with similar properties. To invest more in the production of nucleic acid-based therapies, the manufacturers in this industry are engaging in new partnerships, acquisitions, collaborations, agreements, mergers, and business expansions with contract development and manufacturing organizations (CDMOs). In December 2016, Ajinomoto Co., Inc. and OmniChem N.V. ("OmniChem") agreed to acquire all allocated and outstanding shares of GeneDesign, Inc., a significant Japanese contract development and manufacturing organization (CDMO1) for nucleic acid therapeutics. This acquisition will accelerate the company's expansion in contract development and manufacturing organizations for nucleic acid medicines.

Increasing demand for mRNA-based novel therapies, rising healthcare expenditures, decreasing manufacturing costs at CDMOs, increasing nucleic acid drug approvals, and the rapid adoption of advanced nucleic acid technologies for disease treatment and diagnosis are expected to drive market growth over the next few years. Challenges in the supply chain and targeted delivery, maintaining efficacy and minimizing off-target toxicity, and a lack of expertise in nucleic acid manufacturing will restrain market expansion.

North America is the fastest-growing market at the regional level due to increasing R&D activities, the presence of new competitors, and high demand for nucleic acid therapeutics, primarily due to the COVID-19 outbreak and improved reimbursement policies. On the other hand, the increased prevalence of genetic disorders, the expansion of biopharmaceutical industries, and the development of medical technologies are anticipated to propel the Asia-Pacific nucleic acid therapeutics CDMO market.

Major key players in the nucleic acid therapeutics CDMO market are Agilent Technologies, Inc., Ajinomoto Co. Inc., Bachem Holding AG., Biospring GmbH, Corden Pharma International, Danaher Corporation, Guangzhou Ruibo Biotechnology Co., Ltd., KNC Laboratories Co., Ltd., LGC Limited, Merck KGaA, Nippon Shokubai Co., Ltd., Nitto Denko Avecia Inc, QIAGEN N.V., S.T. Pharm Co Ltd, Sumitomo Chemical Co., Ltd., Syngene International Limited, Thermo Fisher Scientific Inc., Wuxi AppTec, Yamasa Corporation, Laboratorios Farmacéuticos Rovi, S.A., Sartorius AG (BIA Separations), AGC Biologics, FUJIFILM Diosynth Biotechnologies, Hanmi Pharmaceutical, Arranta Bio (Recipharm), ST Pharm, BioCina Pty Ltd., Curia Global, Inc. and Other Prominent Players.

Key Industry Developments:
• In June 2022, Merck agreed with Agilent Technologies to develop Process Analytical Technologies (PAT). Merck and Agilent Technologies are filling a void in the downstream PAT market through this partnership. Merck expands real-time monitoring and automated process control of key process parameters (CPPs) and critical quality attributes (CQAs) to downstream processing through the combination of its bioprocess portfolio with Agilent Technologies' sophisticated analytical technologies.
• In June 2022, CordenPharma expanded its xRNA capabilities at its Caponago, Italy, plant for sterile injectables. The business claims to have invested over €10 million in a new formulation, research, and manufacturing areas for Lipid Nanoparticles (LNP). The expansion will help clients go from pre-clinical to clinical development of xRNA-based treatments (mRNA, siRNA, saRNA, microRNA, etc.), accelerating the delivery of their new medicinal solutions into clinical stages and beyond.
• In Feb 2022, Recipharm has acquired Arranta Bio. The acquisition is a cornerstone of Recipharm's strategy to provide scientifically differentiated contract development and manufacturing services for ATMPs to innovative drug developers in the Biologics market. It builds on the capabilities acquired through the recently announced GenIbet transaction and the acquisition of Vibalogics.
• In June 2021, Danaher Corporation announced that it would add protein production, plasmid DNA, and mRNA services to its bulging life sciences portfolio by acquiring Aldevron. Through the acquisition, Danaher adds contract manufacturing services.
• In August 2020, Agilent Technologies Inc. announced it would extend its advanced production facility in Frederick, Colorado, that develops and produces "oligos," which are short DNA and RNA molecules used to make nucleic acid-based therapeutics. Oligos hold the potential to be used in inventing treatments for cancer, COVID-19, cardiovascular disease, rare and infectious diseases, and other conditions. The expansion has increased the current capacity for manufacturing therapeutic oligos at the Frederick site.

Interested in Buying @ https://www.insightaceanalytic.com/enquiry-before-buying/1348

Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023-2031 based on Technology
• Column-Based Method
• Microarray-Based Method

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023-2031 based on Products
• Standard Nucleic Acid
• Micro-Scale Nucleic Acid
• Large-Scale Nucleic Acid
• Custom Nucleic Acid
• Modified Nucleic Acid
• Primers
• Probes
• Other Nucleic Acid
• Other Services

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023-2031 based on Chemical Synthesis
• Solid-Phase Oligonucleotide Synthesis
• Liquid-Phase Oligonucleotide Synthesis

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023-2031 based on End-Users
• Pharmaceutical Companies
• Academic Research Institute
• Diagnostic Laboratories

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023-2031 based on Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2023-2031
• U.S.
• Canada

Europe Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2023-2031
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2023-2031
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2023-2031
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2023-2031
• GCC Countries
• South Africa
• Rest of Middle East & Africa

For More Information @ https://www.insightaceanalytic.com/customisation/1348

InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: https://www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Follow Us @ https://www.linkedin.com/company/insightace-analytic-pvt-ltd/

Subscribe Our Exclusive Newsletters @ https://www.linkedin.com/newsletters/latest-market-research-reports-6929319878155739136/

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.